Creatine's edge may not carry to elite athletes

Creatine became a routine purchase for competitive athletes across many sports, and the proposed reason is straightforward: loading it raises muscle creatine and phosphocreatine, which should speed ATP resynthesis, delay the onset of muscular fatigue and help recovery between repeated bouts of high-intensity work. That mechanism is a laboratory argument, though, and it does not automatically say what happens on race day for someone who is already highly trained. This review set out to ask a narrower and more awkward question: in whom, and under what conditions, has the ergogenic effect actually been demonstrated?

The authors carried out a critical review of the published creatine literature as it stood, focusing on who the participants were and what tasks they performed rather than simply counting positive trials. They separated studies of untrained subjects completing several exercise bouts under controlled laboratory conditions from the much smaller set of studies in highly trained athletes performing single, competition-like exercise tasks. They also considered the proposed physiological mechanism, from muscle creatine and phosphocreatine loading through to ATP resynthesis and fatigue onset, to judge whether the mechanism predicted benefit in elite competition. The abstract reports the conclusions qualitatively and gives no pooled effect estimates.

The headline pattern was one of population and protocol, not of a flat null. Where ergogenic effects were found, they were generally in untrained subjects doing multiple exercise bouts in the laboratory. The limited body of data available on highly trained athletes performing single competition-like tasks indicated that this group did not benefit from supplementation. On that basis the authors concluded that the widespread use of creatine specifically to improve competition performance did not appear justified. They kept one possibility open: elite athletes might still gain from a greater capacity to repeat high-intensity efforts, in training or in sports such as soccer and basketball that demand repeated bursts, but noted this needed scientific confirmation.

This is a critical appraisal rather than a quantitative pooling, and it is an early snapshot of a literature that has since grown considerably, so it should be read as a caution about extrapolation rather than a final verdict. Its most durable point is methodological: results from untrained people in repeated laboratory bouts do not transfer neatly to trained athletes in a single competitive effort. The open questions it named are the interesting ones — whether repeated-sprint team sports respond, and whether any benefit arrives indirectly through better quality training rather than through a one-off performance jump.

The useful takeaway is about the fine print behind supplement claims rather than about creatine being useless. A finding that holds in untrained volunteers doing several laboratory bouts is not the same finding as an improvement in a single competitive performance by someone already highly trained, and this review argued that on the elite, single-task evidence available at the time the benefit was not there. If your interest is repeated high-intensity efforts, the authors regarded that as a plausible but unproven case. It is a reason to look at what population and task any performance claim was actually tested in.